Imatinib is an oral Tyrosine kinase inhibitor (TKI) medication that targets the BCR-ABL protein present in chronic myeloid leukemia (CML) patients. In 2000, our physicians at Weill Cornell Medicine participated in a clinical trial to evaluate Imatinib, which was investigational at the time, for the treatment of CML. This study ultimately was transformative as Imatinib served as a targeted therapy able to address the underlying abnormalities that cause the cancer to divide and multiply. These great results led to the FDA approval of Imatinib as the first oral inhibitor for CML. Since then, Imatinib has become the standard treatment for CML patients. Side effects of the drug are typically mild, such as diarrhea, muscle pain, fluid buildup, fatigue, and nausea, but often improve over time.
Learn more: [ Ссылка ]
